(NASDAQ: HROW) Harrow's forecast annual revenue growth rate of 32.19% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 9.09%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.27%.
Harrow's revenue in 2024 is $130,193,000.On average, 1 Wall Street analysts forecast HROW's revenue for 2024 to be $6,315,060,608, with the lowest HROW revenue forecast at $6,315,060,608, and the highest HROW revenue forecast at $6,315,060,608. On average, 1 Wall Street analysts forecast HROW's revenue for 2025 to be $8,281,577,130, with the lowest HROW revenue forecast at $8,281,577,130, and the highest HROW revenue forecast at $8,281,577,130.
In 2026, HROW is forecast to generate $10,713,112,394 in revenue, with the lowest revenue forecast at $10,713,112,394 and the highest revenue forecast at $10,713,112,394.